- Home
- XP vs HALO Comparison
XP vs HALO Comparison
Compare XP & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- HALO
- Stock Information
- Founded
- XP 2001
- HALO 1998
- Country
- XP Cayman Islands
- HALO United States
- Employees
- XP N/A
- HALO N/A
- Industry
- XP Investment Bankers/Brokers/Service
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XP Finance
- HALO Health Care
- Exchange
- XP Nasdaq
- HALO Nasdaq
- Market Cap
- XP 7.5B
- HALO 7.4B
- IPO Year
- XP 2019
- HALO N/A
- Fundamental
- Price
- XP $18.91
- HALO $47.91
- Analyst Decision
- XP Buy
- HALO Buy
- Analyst Count
- XP 6
- HALO 9
- Target Price
- XP $20.83
- HALO $63.56
- AVG Volume (30 Days)
- XP 7.1M
- HALO 3.0M
- Earning Date
- XP 05-27-2025
- HALO 05-06-2025
- Dividend Yield
- XP 3.45%
- HALO N/A
- EPS Growth
- XP 14.90
- HALO 55.40
- EPS
- XP 1.33
- HALO 3.76
- Revenue
- XP $2,627,582,667.00
- HALO $1,084,306,000.00
- Revenue This Year
- XP $19.66
- HALO $24.79
- Revenue Next Year
- XP $12.78
- HALO $22.65
- P/E Ratio
- XP $13.92
- HALO $13.36
- Revenue Growth
- XP 14.10
- HALO 25.64
- 52 Week Low
- XP $10.82
- HALO $41.28
- 52 Week High
- XP $22.23
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- XP 80.46
- HALO 32.31
- Support Level
- XP $15.51
- HALO $58.38
- Resistance Level
- XP $16.29
- HALO $69.94
- Average True Range (ATR)
- XP 0.50
- HALO 3.37
- MACD
- XP 0.31
- HALO -1.11
- Stochastic Oscillator
- XP 94.84
- HALO 1.78
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.